Anthony J. Hatswell

Bicester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 68 publications

Methods for Analysing Patient-Level Utility Data: Insights from the Literature Review and Recent NICE Technology Appraisals.

Methods for Analysing Patient-Level Utility Data: Insights from the Literature Review and Recent NICE Technology Appraisals.

Journal: PharmacoEconomics

Published: March 06, 2026

Comparative Effectiveness of Valoctocogene Roxaparvovec and Efanesoctocog Alfa in the Treatment of Severe Hemophilia A: A Matching-Adjusted Indirect Comparison of Bleeding Frequency.

Comparative Effectiveness of Valoctocogene Roxaparvovec and Efanesoctocog Alfa in the Treatment of Severe Hemophilia A: A Matching-Adjusted Indirect Comparison of Bleeding Frequency.

Journal: Advances in therapy

Published: June 11, 2025

A plain language summary on indirectly comparing bleeding after valoctocogene roxaparvovec gene therapy to bleeding with emicizumab prophylaxis.

A plain language summary on indirectly comparing bleeding after valoctocogene roxaparvovec gene therapy to bleeding with emicizumab prophylaxis.

Journal: Expert review of hematology

Published: March 17, 2025

R Packages for Matching-Adjusted Indirect Comparison: Differences in Usability and Identical Results From Reuse of Prior Code.

R Packages for Matching-Adjusted Indirect Comparison: Differences in Usability and Identical Results From Reuse of Prior Code.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: December 18, 2024

An Evaluation of an Algorithm for the Selection of Flexible Survival Models for Cancer Immunotherapies: Pass or Fail?

An Evaluation of an Algorithm for the Selection of Flexible Survival Models for Cancer Immunotherapies: Pass or Fail?

Journal: PharmacoEconomics

Published: August 12, 2024

Treatment Effect Waning in Immuno-oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence with Proposals to Guide Modelling.

Treatment Effect Waning in Immuno-oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence with Proposals to Guide Modelling.

Journal: PharmacoEconomics

Published: July 23, 2024

Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK.

Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK.

Journal: Targeted oncology

Published: January 27, 2024

An Attribution of Value Framework for Combination Treatments.

An Attribution of Value Framework for Combination Treatments.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: September 07, 2023

Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer.

Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer.

Journal: PharmacoEconomics

Published: August 14, 2023

Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A.

Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A.

Journal: Advances in therapy

Published: August 11, 2023

A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.

A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.

Journal: Expert review of anticancer therapy

Published: February 01, 2023

Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.

Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: January 13, 2023

Showing 1-12 of 68

Last Updated: 09/26/2026